Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020)
Scholar Rock Holding (SRRK) recorded quarterly Non-Current Deffered Revenue of $33.2 million in Q4 2020, down 14.32% quarter-over-quarter from $38.7 million in Q3 2020, and down 28.6% on a YoY basis from $46.5 million in Q1 2020.
Scholar Rock Holding (SRRK) Non-Current Deffered Revenue (2017 - 2020) Analysis & Trends
Scholar Rock Holding's Non-Current Deffered Revenue history runs 4 years deep, the most recent figure standing at $33.2 million for Q4 2020.
- In Q4 2020, Non-Current Deffered Revenue fell 28.6% year-over-year to $33.2 million; the TTM figure through Dec 2020 stood at $33.2 million (down 28.6% YoY), while the FY2020 annual figure was $33.2 million, down 28.6% from the prior year.
- Non-Current Deffered Revenue was $33.2 million for Q4 2020 at Scholar Rock Holding, down from $38.7 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $46.5 million in Q4 2019 to a low of $468000.0 in Q4 2017.
- Historically, Non-Current Deffered Revenue has averaged $28.6 million across 4 years, with a median of $33.8 million in 2019.
- The sharpest annual moves came in 2018 and 2020: Non-Current Deffered Revenue jumped 9022.86% in 2018, then retreated 28.6% in 2020.
- A 4-year view of Non-Current Deffered Revenue shows it stood at $468000.0 in 2017, then surged by 9022.86% to $42.7 million in 2018, then gained by 8.89% to $46.5 million in 2019, then declined by 28.6% to $33.2 million in 2020.
- The last three Non-Current Deffered Revenue figures came in at $33.2 million (Q4 2020), $38.7 million (Q3 2020), and $38.1 million (Q2 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 33.19 Mn |
| Sep 30, 2020 | 38.74 Mn |
| Jun 30, 2020 | 38.12 Mn |
| Mar 31, 2020 | 46.11 Mn |
| Dec 31, 2019 | 46.49 Mn |
| Sep 30, 2019 | 29.73 Mn |
| Jun 30, 2019 | 31.24 Mn |
| Mar 31, 2019 | 34.43 Mn |
| Dec 31, 2018 | 42.70 Mn |
| Sep 30, 2018 | 886,000.00 |
| Jun 30, 2018 | 681,000.00 |
| Dec 31, 2017 | 468,000.00 |